Is BMY's Deep Pipeline the Key to Its Next Growth Phase?

Key Takeaways BMY highlighted pipeline assets with multi-billion-dollar potential at the J.P. Morgan Healthcare Conference.BMY expects key data in 2026 for milvexian and later this year for admilparant in pulmonary fibrosis.BMY sees encouraging early uptake for Cobenfy as it pursues label expansion in Alzheimer's disease.Bristol Myers Squibb (BMY) highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan Healthcare Conference, held earlier this month.Key pipeline candidates ...